These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 37934103)

  • 1. TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors.
    Edwards AC; Stalnecker CA; Jean Morales A; Taylor KE; Klomp JE; Klomp JA; Waters AM; Sudhakar N; Hallin J; Tang TT; Olson P; Post L; Christensen JG; Cox AD; Der CJ
    Cancer Res; 2023 Dec; 83(24):4112-4129. PubMed ID: 37934103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy.
    Mukhopadhyay S; Huang HY; Lin Z; Ranieri M; Li S; Sahu S; Liu Y; Ban Y; Guidry K; Hu H; Lopez A; Sherman F; Tan YJ; Lee YT; Armstrong AP; Dolgalev I; Sahu P; Zhang T; Lu W; Gray NS; Christensen JG; Tang TT; Velcheti V; Khodadadi-Jamayran A; Wong KK; Neel BG
    Cancer Res; 2023 Dec; 83(24):4095-4111. PubMed ID: 37729426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Hepatocyte Growth Factor/MET Signaling as a Mechanism of Acquired Resistance to a Novel YAP1/TEAD Small Molecule Inhibitor.
    Moure CJ; Vara B; Cheng MM; Sondey C; Muise E; Park E; Vela Ramirez JE; Su D; D'Souza S; Yan Q; Yeung CS; Zhang M; Mansueto MS; Linn D; Buchanan M; Foti R; DiMauro E; Long B; Simov V; Barry ER
    Mol Cancer Ther; 2024 Aug; 23(8):1095-1108. PubMed ID: 38691847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. YAP1/TAZ-TEAD transcriptional networks maintain skin homeostasis by regulating cell proliferation and limiting KLF4 activity.
    Yuan Y; Park J; Feng A; Awasthi P; Wang Z; Chen Q; Iglesias-Bartolome R
    Nat Commun; 2020 Mar; 11(1):1472. PubMed ID: 32193376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of resistance mechanisms to small-molecule inhibition of TEAD-regulated transcription.
    Kulkarni A; Mohan V; Tang TT; Post L; Chan YC; Manning M; Thio N; Parker BL; Dawson MA; Rosenbluh J; Vissers JH; Harvey KF
    EMBO Rep; 2024 Sep; 25(9):3944-3969. PubMed ID: 39103676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippo pathway effectors YAP, TAZ and TEAD are associated with EMT master regulators ZEB, Snail and with aggressive phenotype in phyllodes breast tumors.
    Akrida I; Makrygianni M; Nikou S; Mulita F; Bravou V; Papadaki H
    Pathol Res Pract; 2024 Oct; 262():155551. PubMed ID: 39153238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All Roads Lead to Rome: YAP/TAZ Activity Influences Efficacy of KRASG12C Inhibitors.
    Johnson CW; Haigis KM
    Cancer Res; 2023 Dec; 83(24):4005-4007. PubMed ID: 38098448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TEAD Inhibitors Sensitize KRAS
    Tammaccaro SL; Prigent P; Le Bail JC; Dos-Santos O; Dassencourt L; Eskandar M; Buzy A; Venier O; Guillemot JC; Veeranagouda Y; Didier M; Spanakis E; Kanno T; Cesaroni M; Mathieu S; Canard L; Casse A; Windenberger F; Calvet L; Noblet L; Sidhu S; Debussche L; Moll J; Valtingojer I
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer.
    Jung O; Baek MJ; Wooldrik C; Johnson KR; Fisher KW; Lou J; Ricks TJ; Wen T; Best MD; Cryns VL; Anderson RA; Choi S
    EMBO J; 2024 May; 43(9):1740-1769. PubMed ID: 38565949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation.
    Lin KC; Moroishi T; Meng Z; Jeong HS; Plouffe SW; Sekido Y; Han J; Park HW; Guan KL
    Nat Cell Biol; 2017 Jul; 19(8):996-1002. PubMed ID: 28752853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
    Hagenbeek TJ; Zbieg JR; Hafner M; Mroue R; Lacap JA; Sodir NM; Noland CL; Afghani S; Kishore A; Bhat KP; Yao X; Schmidt S; Clausen S; Steffek M; Lee W; Beroza P; Martin S; Lin E; Fong R; Di Lello P; Kubala MH; Yang MN; Lau JT; Chan E; Arrazate A; An L; Levy E; Lorenzo MN; Lee HJ; Pham TH; Modrusan Z; Zang R; Chen YC; Kabza M; Ahmed M; Li J; Chang MT; Maddalo D; Evangelista M; Ye X; Crawford JJ; Dey A
    Nat Cancer; 2023 Jun; 4(6):812-828. PubMed ID: 37277530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
    Crawford JJ; Bronner SM; Zbieg JR
    Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
    [No Abstract]   [Full Text] [Related]  

  • 14. Loss of
    Goto H; Nishio M; To Y; Oishi T; Miyachi Y; Maehama T; Nishina H; Akiyama H; Mak TW; Makii Y; Saito T; Yasoda A; Tsumaki N; Suzuki A
    Development; 2018 Mar; 145(6):. PubMed ID: 29511023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
    Rao G; Kim IK; Conforti F; Liu J; Zhang YW; Giaccone G
    Eur J Cancer; 2018 Aug; 99():37-48. PubMed ID: 29902613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic Hedgehog-Smoothened Signaling Depends on YAP1‒TAZ/TEAD Transcription to Restrain Differentiation in Basal Cell Carcinoma.
    Yuan Y; Salinas Parra N; Chen Q; Iglesias-Bartolome R
    J Invest Dermatol; 2022 Jan; 142(1):65-76.e7. PubMed ID: 34293352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non-Small Cell Lung Cancer.
    Prahallad A; Weiss A; Voshol H; Kerr G; Sprouffske K; Yuan T; Ruddy D; Meistertzheim M; Kazic-Legueux M; Kottarathil T; Piquet M; Cao Y; Martinuzzi-Duboc L; Buhles A; Adler F; Mannino S; Tordella L; Sansregret L; Maira SM; Graus Porta D; Fedele C; Brachmann SM
    Cancer Res; 2023 Dec; 83(24):4130-4141. PubMed ID: 37934115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanosignaling YAP/TAZ-TEAD Axis Regulates the Immunomodulatory Properties of Mesenchymal Stem Cells.
    Yoshii H; Kajiya M; Yoshino M; Morimoto S; Horikoshi S; Tari M; Motoike S; Iwata T; Ouhara K; Ando T; Yoshimoto T; Shintani T; Mizuno N
    Stem Cell Rev Rep; 2024 Jan; 20(1):347-361. PubMed ID: 37917410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the YAP/TAZ-TEAD Transcriptional Complex in the Metabolic Control of TRAIL Sensitivity by the Mevalonate Pathway in Cancer Cells.
    El Yousfi Y; Mora-Molina R; López-Rivas A; Yerbes R
    Cells; 2023 Sep; 12(19):. PubMed ID: 37830584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric Modulation of the YAP/TAZ-TEAD Interaction by Palmitoylation and Small-Molecule Inhibitors.
    Mills KR; Misra J; Torabifard H
    J Phys Chem B; 2024 Apr; 128(16):3795-3806. PubMed ID: 38606592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.